文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

低氧血症性呼吸衰竭的氧合目标与长期认知及肺功能:一项临床试验

Oxygenation Targets and Long-Term Cognitive and Pulmonary Functions in Hypoxemic Respiratory Failure: A Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2026-01-01
一句话结论在ICU低氧血症性呼吸衰竭存活者中,PaO2目标60 vs 90 mmHg的1年认知功能相似,但60 mmHg组DlCO较90 mmHg组低5个百分点。

该研究基于Handling Oxygenation Targets in the ICU和Handling Oxygenation Targets in COVID-19两项试验的3654例随机患者,1年存活1916例(52.4%),其中1244例(64.9%)符合条件。共纳入417/1244例(33.5%)符合条件的存活者,占原始试验人群的11.4%,评估PaO2目标60 vs 90 mmHg对1年认知功能(Repeatable Battery for the Assessment of Neuropsychological Status全局评分)和肺功能(预测DlCO百分比)的影响。认知评分在低氧合组187例(均值78,SD 19)与高氧合组188例(均值76,SD 21)间校正后平均差为2(95%CI -2至6)。DlCO在低氧合组192例(均值68%,SD 22)与高氧合组195例(均值73%,SD 25)间校正后平均差为-5个百分点(95%CI -9至-1)。结论认为PaO2目标60 vs 90 mmHg似乎导致相似的认知损害,但可能降低ICU低氧血症性呼吸衰竭存活者的肺弥散能力。

要点

  • 在ICU低氧血症性呼吸衰竭存活者中,PaO2目标60 vs 90 mmHg的1年认知功能全局评分校正后平均差为2(95%CI -2至6),两组相似。
  • PaO2目标60 mmHg组1年DlCO均值为68%(SD 22),90 mmHg组为73%(SD 25),校正后平均差为-5个百分点(95%CI -9至-1),低氧合目标组肺弥散能力较低。
  • 该随访纳入417/1244例(33.5%)符合条件的1年存活者,占原始试验人群的11.4%。
  • 认知评分来自低氧合组187例和高氧合组188例,DlCO来自低氧合组192例和高氧合组195例。

适用人群与场景

  • ICU存活者中的急性低氧血症性呼吸衰竭患者,来自Handling Oxygenation Targets in the ICU和Handling Oxygenation Targets in COVID-19两项试验的1年存活者。
  • 1244例符合条件的1年存活者中纳入417例(33.5%),占原始随机人群3654例的11.4%。

研究设计与关键结果

  • 研究类型为对两项随机试验(Handling Oxygenation Targets in the ICU和Handling Oxygenation Targets in COVID-19)的1年预设计随访分析,原始随机3654例,1年存活1916例(52.4%),符合条件1244例(64.9%),纳入417例(33.5%)。
  • 干预为PaO2目标60 mmHg vs 90 mmHg;主要终点为1年认知功能(Repeatable Battery for the Assessment of Neuropsychological Status全局评分)和肺功能(预测DlCO百分比)。
  • 认知评分:低氧合组187例均值78(SD 19)vs 高氧合组188例均值76(SD 21),校正后平均差2(95%CI -2至6)。
  • DlCO:低氧合组192例均值68%(SD 22)vs 高氧合组195例均值73%(SD 25),校正后平均差-5个百分点(95%CI -9至-1)。

证据类型、等级与局限

  • 证据类型:对两项随机对照试验的1年预设计随访分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,PaO2目标60 vs 90 mmHg似乎导致相似的认知损害,但可能降低ICU低氧血症性呼吸衰竭存活者的肺弥散能力(DlCO校正后平均差-5个百分点,95%CI -9至-1)。

指南或共识出处

  • Handling Oxygenation Targets in the ICU(NCT03174002)和Handling Oxygenation Targets in COVID-19(NCT04425031)试验的1年随访分析。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: In ICU patients, lower oxygenation targets may impair long-term cognitive function, whereas higher targets may impair long-term pulmonary function.

OBJECTIVES: We sought to assess the effects of a PaO2 target of 60 versus 90 mm Hg on 1-year cognitive and pulmonary functions in ICU survivors of acute hypoxemic respiratory failure.

METHODS: A total of 3,654 patients were randomized in the Handling Oxygenation Targets in the ICU and the Handling Oxygenation Targets in COVID-19 trials: 1,916 (52.4%) survived at 1 year, of which 1,244 (64.9%) were eligible. We assessed two preplanned 1-year outcomes: cognitive function, measured using the global score of the Repeatable Battery for the Assessment of Neuropsychological Status, and pulmonary function, evaluated as the percentage of predicted DlCO.

MEASUREMENTS AND MAIN RESULTS: A total of 417/1,244 (33.5%) eligible survivors were included, representing 11.4% of the original trial population. The Global Repeatable Battery for the Assessment of Neuropsychological Status score was obtained from 187 survivors in the lower oxygenation group (mean = 78; SD = 19) and 188 in the higher oxygenation group (mean = 76; SD = 21); adjusted mean difference = 2 (95% confidence interval = -2 to 6). DlCO was measured in 192 survivors in the lower oxygenation group (mean = 68%; SD = 22) and 195 in the higher oxygenation group (mean = 73%; SD = 25); adjusted mean difference = -5 percentage points (95% CI = -9 to -1).

CONCLUSIONS: A PaO2 target of 60 versus 90 mm Hg appeared to result in similar cognitive impairment but might reduce pulmonary diffusion capacity in ICU survivors of hypoxemic respiratory failure included in this 1-year follow-up.Clinical trial registered with www.

CLINICALTRIALS: gov (NCT03174002 and NCT04425031).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Crescioli E, Klitgaard TL, Riis JØ, et al. Oxygenation Targets and Long-Term Cognitive and Pulmonary Functions in Hypoxemic Respiratory Failure: A Clinical Trial. Am J Respir Crit Care Med. 2026. PMID: 40920961. doi:10.1164/rccm.202412-2499OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。